Group items tagged

Pharmacogenomics can play an important role in identifying responders and non-responders to medications, avoiding adverse events, and optimizing drug dose. Drug labeling may contain information on genomic biomarkers and can describe: Drug exposure and clinical response variability Risk for adverse events Genotype-specific dosing Mechanisms of drug action Polymorphic drug target and disposition genes The table below lists FDA-approved drugs with pharmacogenomic information in their labeling. The labeling for some, but not all, of the products includes specific actions to be taken based on the biomarker information. Pharmacogenomic information can appear in different sections of the labeling depending on the actions. For more information, please refer to the appropriate labeling guidance.

Science behind drug abuse; website for teens.  Includes pages on drug facts, blog, national drug facts week event, educator and parent pages, as well as teen prescription drug abuse.

A study in monkeys offers the first evidence that a leading drug developed to fight Ebola works against the strain causing the current outbreak in West Africa. Six animals were infected with a very high dose of the virus and then, three days later, half were given the drug, TKM-Ebola-Makona, which was designed specifically to fight the West African strain. The monkeys that received the drug survived, but all three untreated monkeys died, researchers reported on Wednesday in the journal Nature.

"Designing drugs" sounds trendy, but it accurately describes how some remarkably effective drugs are developed. In this case study we'll follow the steps of drug design, from initial research on the targeted disease, to the drug's use in humans. Gleevec (STI-571) is our example.

This video excerpt from NOVA examines the promise and realities of developing drugs designed to treat genetic disorders. The video presents the story of one patient, Michael McCarrick, whose lungs were devastated from years of suffering from cystic fibrosis. After researchers identified the gene involved in cystic fibrosis, it took decades to find ways to fortify the faulty protein responsible for the serious illness. While two drugs, including one called Kalydeco, offer a small number of patients hope that they will not have to endure a lung transplant, it may be years and several hundred million more development dollars before effective drugs are available for a wider population.

She wanted to understand the effects of mutations that the gene for p53 is prone to. In dozens of simulations, she and her colleagues tracked how common p53 mutations further destabilize the already floppy protein, distorting it and preventing it from binding to DNA. Some simulations also revealed something else: a fingerhold for a potential drug. Once in a while, a small cleft forms in the mutated protein's core. When Amaro added virtual drug molecules into her models, the compounds lodged in that cleft, stabilizing p53 just enough to allow it to resume its normal functions.

alchol anabolic steroids meth perscription drugs bath salts cocaine cough and cold meds heroin inhalents salvia spice marijuana MDMA tobacco

Within a year, Stein's team had designed a clinical trial protocol that turned standard research practices around 180 degrees, launching what it now calls the Signature Clinical Trial Program. Instead of a patient traveling to one of several research sites, Novartis would send the investigational drugs to his or her local oncologist's office. Instead of testing hundreds or thousands of genetically unscreened patients, the company would accept only patients who had the genetic markers the drugs were supposed to target. Instead of waiting months, patients could access the treatments in two or three weeks. Instead of running a large-scale trial to investigate one or two questions, clinicians could conduct smaller, rapid proof-of-concept studies to quickly rule out the tumor types that don't respond to a study agent and identify other tumor types that are potentially treatable with the drug and worthy of further study.

New immune system-boosting cancer drugs have in clinical trials saved the lives of many people with seemingly untreatable melanoma or lung cancer, but the drugs seem useless against colon cancer. One exception-a man with colon cancer whose metastatic tumors vanished for several years after he was treated in 2007-piqued researchers' interest. They suspected his recovery might have to do with the large number of mutations in his tumors. Now, a small clinical trial suggests that even cancer patients with types of tumors that were thought to be impervious to the new drugs could benefit if those malignancies have the right error-riddled DNA signature, a result that could help 3% to 4% of cancer patients.

When a person dies from cancer, the culprit is usually not the original tumor but rather the cancerous cells that spread throughout the body and replicate in distant organs, a process called metastasis. Researchers have long known that metastasizing cancer cells slip their bonds and avoid immune detection by altering the sugars on their surfaces. They've even come up with a would-be drug to prevent such sugar alterations. But that compound interferes with needed sugars on normal cells, too, with lethal results in animals. Now, Dutch researchers report that they've packaged the drug in nanoparticles targeted exclusively to cancer cells, and they've shown that this combination prevents cancer cells from metastasizing in mice.  

Scientists said Wednesday a new drug tested on monkeys provided an astonishingly effective shield against an animal version of the AIDS virus, a major gain in the quest for an HIV vaccine. Macaque monkeys given the drug were able to fend off high, repeated doses of the simian version of the human immunodeficiency virus (HIV), they reported in the journal Nature.

The US Food and Drug Administration has approved a first-of-a-kind drug that uses the herpes virus to infiltrate deadly skin cancer tumours, reducing their size in some cases.

This flipped case study tells the story of Joyce, a biology student who notices the development of some unusual symptoms (foot slapping and slurred speech) in her mother. In an effort to understand the cause, Joyce views a documentary-style trigger video (created by the case author) that suggests to Joyce that her mom may in fact have amyotrophic lateral sclerosis or ALS. The rest of the case walks Joyce through understanding how normal neurons compare to neurons in ALS patients and how that might affect muscle function. The case explores the link between genes, particularly SOD-1, to the formation of malformed proteins and its potential role in the development of ALS. The case concludes with a discussion of drug development and highlights the timeline and costs associated with drug discovery as Joyce becomes concerned about the lack of drugs in the pipeline for ALS, which her mother is ultimately diagnosed with. The case is appropriate for a number of classes including general biology, biotechnology, anatomy and physiology, upper level-cell biology, or any human health and disease-related course.

overview of the effects of different types of drug and alcohol use during pregnancy

ROME (Thomson Reuters Foundation) - If drug-resistant infections in people and animals are allowed to spread unchecked, some 28 million people will fall into poverty by 2050, and a century of progress in health will be reversed, the World Bank said on Monday. By 2050, annual global GDP would fall by at least 1.1 percent, although the loss could be as much as 3.8 percent - the equivalent of the 2008 financial crisis - the Bank said in a report released ahead of a high-level meeting on the issue at the United Nations in New York this week.

Inflammation may help you fight off invading microbes, but it can also kill you, leading to insufficient blood flow and even organ failure. A new study shows that some cancer drugs may be able to quell the excessive inflammation that occurs in conditions such as sepsis, which is responsible for more than 250,000 deaths in the United States each year.

Five people living with HIV are currently free of the detectable virus after taking part in a new vaccine-based therapy.  The patients are also not taking daily antiretroviral drugs, with one having been drug free for a total of seven months; a milestone moment in a move towards a future where HIV treatment doesn't require ART.

Before the discovery of insulin in 1921, being diagnosed with Type 1 diabetes was a death sentence. Despite the successful management of diabetes with purified animal insulin, potentially severe side effects were abundant, and alternative ways to produce insulin were needed. This case study guides students through the history of using insulin to treat diabetes, focusing on the development of recombinant DNA technology and the world's first bioengineered drug, recombinant human insulin, which is now used worldwide to treat diabetes. Through the course of this case, students consider the central dogma of molecular biology, the development of recombinant DNA technology, drug design, the importance of recombinant proteins to our society, and the ethical analysis and debates that occur as a result of some scientific discoveries. This case was developed as an introduction to an upper-division biotechnology course focusing on recombinant protein design and production, but could also be used in molecular biology, biochemistry, or introductory biology courses to highlight recombinant DNA and biotechnology.

When researchers tested wastewater before and after treatment at a Milwaukee-area treatment plant, they found that two drugs-the anti-epileptic carbamazepine and antibiotic ofloxacin-came out at higher concentrations than they went in. The study suggests the microbes that clean our water may also piece some pharmaceuticals back together.

New research shows butterflies use nectar to drug unsuspecting ants with mind-altering chemicals. The Japanese oakblue butterfly (Narathura japonica) enlists the help of ants (Pristomyrmex punctatus) to stand guard and protect its growing caterpillars (pictured) from predators such as wasps and spiders.